Kornimate/medical-research-clean huggingface dataset:
the feasibility and examination of the effects of floatation-based rest on a community sample with ptsd

Conditions: Post-Traumatic Stress Disorders

Summary: this project is being done to explore the effects floating has on individuals who have a history of trauma with stress related symptoms.

this pilot study looks to further the current floatation-based rest literature by exploring the therapy's effectiveness within a community-based sample of adults with ptsd. this type of sample allows the study the opportunity to recruit both veteran and civilian subjects, two populations that can suffer from this clinical diagnosis and stand to benefit from this therapy. this study will: 1. evaluate the psychological effects of floating for a clinical, community sample with ptsd. 2. evaluate the physiological effects of floating for a clinical, community sample with ptsd. 3. evaluate the subjective effects of floating for a clinical, community sample with ptsd.

Eligibility criteria:
inclusion criteria: * has posttraumatic stress disorder (ptsd) as confirmed by the pcl-5 * 18-60 years of age exclusion criteria: * history of neurological conditions (e.g., epilepsy, stroke, severe traumatic brain injury, parkinson's disease, alzheimer's disease or other forms of dementia) * any skin conditions or open wounds that could cause pain when exposed to saltwater * has floated previously * has schizophrenia spectrum or other psychotic disorders * refuses to adhere to the pre-float checklist * non-english speaking * inability to lay comfortably in a shallow pool of water * refuses participation in the floatation-rest sessions * refuses to sign the float liability waiver prior to floating * no communicable disease (e.g.- hiv, hepatitis a, b\& c, tuberculosis, or measles) * no psychoactive drugs or laxatives within the past week from scheduled float. psychoactive drugs include, but are not limited to: methylenedioxymethamphetamine (mdma), lysergic acid diethylamide (lsd), psilocybin, peyote, phencyclidine, ketamine).no recreational drug use (e.g.tetrahydrocannabinol,abuse of prescription medicine) day before or day of study visit. no antihistamine that causes drowsiness and no alcohol the day of the float sessions. * lack of control of bodily functions prior to scheduled float * fresh tattoos that would inhibit ability to float (consult with tattoo artist) * colored/dyed hair less than one week old from scheduled float * body tanning/spay/paint less than one week old from scheduled float * active suicidal ideation

Keywords: floatation-based reduced environmental stimulation therapy ptsd float trauma
non-interventional observational study on the influence of pramipexole on sensory symptoms of restless legs syndrome (rls)

Conditions: Restless Legs Syndrome

Summary: the main goal of this open-label, prospective, non-controlled, non-interventional post marketing surveillance study is to evaluate how pramipexole treatment works when applied in actual practice. in actual practice patients who would have been excluded in the clinical registration studies of pramipexole in moderate to severe primary restless legs syndrome (i.e. those with certain disease histories, co-morbidities and/or demographic characteristics) will also be treated with pramipexole. thus, during this post marketing surveillance study additional information on the efficacy and safety of pramipexole in those patients will be obtained. the objectives of this post marketing surveillance study are: * to investigate the influence of sifrol® (pramipexole) treatment on unpleasant sensory symptoms of restless legs syndrome as measured with the short form of the mcgill pain questionnaire. * to assess if improvement of sensory symptoms correlates with overall restless legs syndrome severity (international restless legs syndrome scale for severity) and with secondary symptoms like sleeping problems and daytime tiredness (items 1 \& 6 from restless legs syndrome-6). * to evaluate if the treatment effect of sifrol on overall restless legs syndrome severity (international restless legs syndrome scale for severity) differs between patients with high pain scores and patients with lower pain scores. * to compare general practitioner and neurologist sites patient populations in terms of demographics, restless legs syndrome severity at visit 1 and treatment outcomes at visit 3. * to evaluate the development of behavioural changes under pramipexole treatment.

study design:

Eligibility criteria:
inclusion criteria: 1. diagnosis of primary moderate to severe restless legs syndrome. 2. patients who are planned to be treated with sifrol® (pramipexole) and where the decision of treatment is made independent of the patients' inclusion into this post marketing surveillance study. 3. male or female patients aged at least 18 years. 4. written informed consent by the patient for study participation. exclusion criteria: 1. any contraindications according to the summary of product characteristics: hypersensitivity to pramipexole or to any of the excipients. 2. previous or ongoing treatment with sifrol® (pramipexole). 3. previous or ongoing treatment with dopamine receptor agonists.
clinical application of near-infrared fluorescence guided localization on breast surgery in benign breast neoplasm.

Conditions: Benign Breast Neoplasm

Summary: near-infrared (nir) fluorescence imaging using indocyanine green (icg) has been used for breast cancer surgery such as sentinel lymph node (sln) mapping and breast cancer localization. in this study, our hypothesis are as following: 1. as inject only indocyanine green (icg), it provide the surgeon visual guidance to ensure better outcome. 2. indocyanine green (icg) permitted accurate preoperative and intraoperative detection of the slns as well as nonpalpable benign brest lesion in patients with breast cancer.

indocyanine green, icg (icg-fluorescence) * icg is the most commonly used fluorophore which approve by fda. * nir-f imaging with icg could be used in various surgeries. for example, sln mapping in breast cancer and localization of liver metastasis, especially superficial lesion * contains sodium iodide, patients who have history of allergy to iodides should be used as caution. nonpalpable benign brest lesion localization * new method for the localization and resection of non-palpable breast lesions. * the breast lesion was correctly localized, and the area of icg corresponded well to the site of the lesions.

Eligibility criteria:
inclusion criteria: * nonpalpable benign breast lesion ≤ 2cm in patients with breast cancer. * patients who need breast biopsy as treatment for breast cancer. * eastern cooperative oncology group performance status 0 or 1 * consented patients with more than 20 years, less than 70 years exclusion criteria: * nonpalpable benign breast lesion ≥ 2cm in patients with breast cancer. * pregnancy * history of severe allergy to icg(indocyanine green) * iode hypersensitiveness

Keywords: near-infrared fluorescence indocyanine green, icg radio-guided surgery breast cancer
early-phase safety of proton therapy equipment

Conditions: Malignant Glioma; Hepatocellular Carcinoma; Head and Neck Malignant Tumor; Prostate Cancer

Summary: the main purpose of this study is to collect the safety data of sumitomo heavy industries' proton therapy equipment for the treatment of solid cancer patients in linkou chang gung memorial hospital, including the patients' early-stage adverse reactions and the efficacy on tumors, as well as to assess the operating functionality of the proton therapy system.

the main purpose of this study is to collect the safety data of sumitomo heavy industries' proton therapy equipment for the treatment of solid cancer patients in linkou chang gung memorial hospital, including the patients' early-stage adverse reactions and the efficacy on tumors, as well as to assess the operating functionality of the proton therapy system. in this study, solid cancer subjects will be treated with sumitomo's proton therapy system. safety and operating functionality data will be collected during the treatment and following-up.

Eligibility criteria:
inclusion criteria: 1. subjects who are pathologically confirmed to be suffering from solid cancer or brain tumor 2. subjects who are measurable or with disease that is evaluable 3. subjects who are expected to survive for at least 90 days 4. subjects who did not receive any treatment that may affect this treatment (such as pei, tae) 4 weeks before they are chosen to receive this treatment 5. ecog performance status (ecog ps): 0, 1 or 2 6. patients who can cooperate with the treatment requirements and maintain the gestures required during the irradiation process 7. patients with well functioning main organs 8. the subject retained main organ functions. 9. the subject age is between 20-75 years old exclusion criteria: 1. subjects who once received radiotherapy on the area planned to be irradiated 2. subjects whose irradiated area has active or persistent infectious disease 3. pregnant or possibly pregnant subjects 4. subjects with other serious complications 5. subjects who are judged by the principle investigator (or co-principle investigator) as unsuitable or because of other reasons described above 6. the subject has the radiotherapy contraindication 7. breast feeding 8. all the subjects have no plan to conception during the treatment and within one year after treatment 9. subject who has any electronic devices in the body which could be affected by radiotherapy and has chance to cause accident. for example: pacemaker, artificial heart, brain and spinal cord stimulation, semi-implantable and implantable electrical stimulation、artificial inner ear ...etc
app delivered brief mindfulness intervention for surgical patients

Conditions: Pain; Anxiety State; Depressive State

Summary: this will be a single-site, five-arm, parallel group randomized control trial involving patients undergoing knee or hip replacement surgery. the investigators will compare five different styles of 5-minute, audio-recoded mindfulness practices delivered via app 7 days before to surgery, 2 days before to surgery, 2 days after surgery, and 6 days after surgery.


Eligibility criteria:
inclusion criteria: * age ≥18, * scheduled to undergo total joint arthroplasty of the knee or hip exclusion criteria: * inability to read english * cognitive impairment preventing completion of study procedures
huddle: heart health: understanding & diagnosing disease by leveraging echocardiograms

Conditions: Cardiovascular Diseases; Heart Diseases

Summary: this study will screen for the presence of cardiovascular disease and provide education about the signs and symptoms of cardiovascular disease and heart disease.


Eligibility criteria:
key eligibility criteria: 1. at least 50 years of age on the day of the screening event 2. informed of the nature of the study, agrees to its provisions, and has provided written informed consent 3. does not have any conditions that would interfere with obtaining an echocardiogram of the heart
improving pain and function in hip fracture

Conditions: Pain; Hip Fractures

Summary: the purpose of this study is to compare two different methods of treating pain after a hip fracture.

this project examines the efficacy and effects of 2 regional anesthesia techniques, femoral nerve blocks (fnb) and fascia iliaca blocks (fib), on the treatment of peri-operative acute hip (femoral neck, intertrochanteric) fracture pain. patients age 60 years and over presenting to two new york city emergency departments with hip fracture will be randomized to receive the intervention or usual care. the intervention includes single injection fnb in the ed followed by insertion of a continuous fib catheter within 24 hours of the single injection fnb plus "as needed" non-opioid/opioid analgesia. usual care patients will receive conventional therapy with regularly scheduled intravenous or oral opioids plus "as needed" non/opioids/opioids. we will examine the impact of the intervention on patients' self reported pain intensity; systemic opioid requirements; post-operative function; incidence of delirium, treatment related side effects; and hospital length of stay and participation in physical therapy.

Eligibility criteria:
inclusion criteria: * all adult patients 60 years of age and over that present to the msmc ed from 8:00 to 20:00 with a radiographically confirmed hip fracture (femoral neck, intertrochanteric, or peri-capsular) will be screened for study eligibility. exclusion criteria: * history of advanced dementia * presence of multiple trauma, pathological fractures, bilateral hip fractures, or previous fracture or surgery at the currently fractured site * patients transferred from another hospital * patients with cirrhosis or liver failure. * the investigators exclude patients with advanced dementia because the investigators will require patients to self-report their pain intensity. * the investigators exclude these categories of hip fracture because they represent patients with atypical or often problematic clinical circumstances. * the investigators exclude patients under age 60 because our focus is on treatment of pain in older adults. younger adults (less than age 60) typically present with fractures of different cause (severe and multiple trauma), are less sensitive to the side effects and complications of opioid therapy, are less likely to have delayed or prolonged functional recovery, and are less sensitive to the adverse and sometimes permanent effects of prolonged bed rest (i.e., from pain) on function. * the investigators exclude patients with hepatic dysfunction because the intervention protocol includes administration of acetaminophen which can provoke liver failure in patients with advanced liver disease.

Keywords: pain hip fractures femoral fractures analgesics opioid nerve block geriatric nerve stimulation
zilver® ptx® v clinical study

Conditions: Peripheral Arterial Disease

Summary: the zilver® ptx® v clinical study is a post-market clinical trial required by the us fda to provide continued evaluation of the safety and effectiveness of the zilver ptx drug-eluting peripheral stent in treatment of narrowing of the femoropopliteal arteries.


Eligibility criteria:
inclusion criteria: * patient has signed and dated the informed consent. * patient has symptomatic vascular disease of the native above-the-knee femoropopliteal arteries. * patient agrees to return for the required follow-up assessments. exclusion criteria: * patient is \< 18 years of age. * patient has significant stenosis of inflow tract not successfully treated before this procedure. * patient lacks at least one patent vessel of runoff with \< 50% stenosis throughout its course.

Keywords: peripheral vascular disease femoral artery popliteal artery drug-eluting stent
the stroke warning information and faster treatment study (swift)

Conditions: Stroke

Summary: the purposes of this study are to determine the effectiveness of an interactive stroke educational program compared to standard educational materials and usual care, to increase stroke knowledge, and to improve emergency room arrival times upon onset of stroke symptoms.

rapid diagnosis and treatment of acute ischemic stroke is critical to reduce disability and death caused by stroke. while recombinant tissue plasminogen activator, or rt-pa, is the only approved treatment for acute ischemic stroke, less than 2-3 percent of individuals with stroke actually receive treatment. the inability to capture acute ischemic stroke cases within 3 hours of symptom onset is one critical factor. populations at highest risk for stroke are significantly undereducated about the need for rapid, intervention upon onset of stroke symptoms. this is especially true among vulnerable populations including african americans, hispanics, and the poor. the purpose of this study is to evaluate the effectiveness of a 2-session, culturally-sensitive, interactive stroke educational program compared to standard educational materials and usual care. in this study, the scientists will determine if the interactive program increases knowledge about stroke, and results in earlier arrival to the emergency room in the case of stroke. the study will enroll 1400 individuals who have had a stroke or transient ischemic attack (tia). participants will be randomized to receive usual medical care--which includes standard educational information on stroke, stroke warning signs and risk factors--or usual medical care plus a 2-session interactive stroke educational program. all participants will be administered pre and post (30 days and 1 year) intervention stroke knowledge/behavior surveys. in additional, participants will be contacted every 12 months to check health status and document new stroke events associated with emergency room arrival time. the swift study is part of the specialized program for translational research in acute stroke (spotrias), which seeks to understand why certain people may be at increased risk for stroke. the goal of the study is to increase stroke knowledge, change behavior, and improve emergency room arrival times upon onset of stroke symptoms.

Eligibility criteria:
inclusion criteria: * diagnosed with cerebral infarction/tia hospitalized at new york presbyterian hospital (milstein hospital and allen pavilion) * 18 year-old and older at onset of the stroke * self-identified as of white, black or hispanic race-ethnicity * living in a household with a telephone exclusion criteria: * patients unable to give informed consent * discharged to nursing home or requiring 24 hour care. * a modified rankin score \> 4 at baseline * severe aphasia or severe cognitive impairment limiting comprehension * pre-stroke dementia history * patients with end stage cancer, or other medical conditions resulting in mortality \</= 1 year

Keywords: stroke interactive educational program acute ischemic stroke
i-matter: investigating an mhealth texting tool for embedding patient-reported data into diabetes management

Conditions: Type2 Diabetes

Summary: this study will integrate a technology-based patient-reported outcome (pro) system \[herein mjs diabetes\] that incorporates patients' perspective of their disease and functional status into the management of type 2 diabetes (t2d) in primary care practices. mjs diabetes is an innovative mobile platform that utilizes text-messaging to capture patients' self-reported pros in real-time; enhance patient engagement through data-driven feedback and motivational messages; and create dynamic visualizations of the pros that can be shared in printed reports, and integrated into the ehr; thus making it actionable for patients and their pcps. using a mixed-methods design, this study will be conducted in 2 phases: 1) a formative phase, using the evidence-based user-centered design approach; and 2) a clinical-efficacy phase. for the formative phase, a qualitative research method will be used to: a) adapt mjs to the needs of pcps and t2d patients; b) integrate mjs diabetes into the ehr system, the primary care practice and the lives of patients with t2d; and c) evaluate the usability of mjs diabetes in a subset of t2d patients and their pcps in order to optimize the tool's performance and workflow integration. for the clinical efficacy phase, a randomized control trial will be used to identify the efficacy of mjs diabetes versus usual care (uc) on reduction hba1c at 12-months, among 282 patients with t2d who receive care in safety-net practices.


Eligibility criteria:
inclusion criteria: primary care provider inclusion criteria: * fulltime primary care provider (md/do, np) practicing at the participating family health centers (fhcs) and, * provide care to at least five patients with a diagnosis of t2d. patient inclusion criteria: * have a diagnosis of t2d for ≥6 months; * have uncontrolled t2d defined as hba1c \>7% documented in the ehr on at least two visits in the past year; * fluency in english or spanish; * be willing to send/receive text messages; and exclusion criteria: * have a diagnosis of t2d for ≥6 months; * have uncontrolled t2d defined as hba1c \>7% documented in the ehr on at least two visits in the past year; * fluency in english or spanish; * be willing to send/receive text messages; and
comparison of molecular-genetic concordance of the primary tumor and brain metastases of colorectal cancer

Conditions: Colorectal Cancer Metastatic; Brain Metastases, Adult; Ras (KRAS or NRAS) Gene Mutation; BRAF Gene Mutation; HER2 Gene Mutation; MSI

Summary: genconcor-1 study is translational research aimed to investigate the concordance of the molecular genetic profile of the primary tumor and brain metastases (bm) of colorectal cancer (crc). the study was conducted by post hoc analysis of pairs of samples of histological material with determination of the mutational status of genes kras, nras, braf, her2 and msi.

brain metastases (bm) from colorectal cancer (crc) are a rare event reported in less than 3% of patients with crc (the reported incidence ranges from 0.27 to 3%). this course is associated with a poor prognosis. treatment of these patients remains challenging. nevertheless, given the rarity of the event, at this time not enough is known about molecular biology of bm from colorectal cancer and its concordance with matched primary tumors. in n.n. blokhin national medical research center of oncology over 26 years (1998-2024) identified 108 patients with bm from crc. of this number, 72 patients had a history of neurosurgical resection of bm. in turn, for 32 patients access to a pair of tumor samples: from the primary tumor and from intracranial metastases. tumor samples will be tested for mutation status of genes kras, nras, braf, her2 and msi. analysis was limited to this pool of genes because of their clinical relevance and potential prognostic information. the molecular profile of the bm will be compared with the corresponding primary tumor with calculation of concordance rate (%).

Eligibility criteria:
inclusion criteria: 1. men and women over 18 years of age. 2. histologically confirmed cancer of the colon or rectum. 3. histologically confirmed metastatic lesion of the brain. 4. neurosurgical resection for brain metastases of colorectal cancer. 5. presence of paired tumor samples (both primary tumor and intracranial material). exclusion criteria: 1. missing one sample from a pair of tumor samples. 2. low quality or lack of tumor material for molecular genetic research.

Keywords: colorectal cancer metastatic brain metastases, adult ras (kras or nras) gene mutation braf gene mutation her2 gene mutation msi
awake prone positioning for covid-19 acute hypoxaemic respiratory failure

Conditions: Survival, Prosthesis; Oxygen Deficiency

Summary: the objective of our study is to evaluate the effectiveness of prone position in preventing intubation or death in spontaneously ventilated patients with covid-19 with acute respiratory failure.

the covid-19 pandemic has challenged the management of hypoxemic respiratory failure as limited icu capacity is strained by a new high-mortality disease and large numbers of patients requiring prolonged periods of hospitalization, as well as respiratory support equipment such as ventilators and intensive care unit (icu) beds. if early and prolonged prone positioning (dv) reduces mortality in invasively ventilated patients with acute respiratory distress syndrome (ards), its role in conscious patients (dv vigil) remains a subject of debate and research. this is a retrospective, monocentric, descriptive and analytical cohort conducted over a period of 22 months from march 2020 to december 2021 and involving 1069 patients hospitalized in the intensive care unit of the chu mohammed vi of oujda for the management of acute respiratory failure caused by covid-19.

Eligibility criteria:
inclusion criteria: * all patients (1069 patients) with ards due to sars-cov2, confirmed by nasopharyngeal swab, who were hospitalized in the covid-19 icu from march 1, 2020 to december 31, 2021 exclusion criteria: * patients with negative crp * younger than 18 years of age * patients who died or intubated on the day of admission * patients presented a contraindication

Keywords: acute respiratory distress syndrome covid-19 conscious prone position survival rate